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ABSTRACT 
Stevioside is a non-caloric sweetener and used as the alternative to sugar in many countries. It has been reported to have promising 
antidiabetic activity. In the present investigation, we have developed a multi-particulate system of stevioside consisting of nonpareil 
pellets for antidiabetic patients. The drug loading on pellets was performed by solvent evaporation and suspension layering method. 
The loaded pellets were evaluated for yield (%), drug loading efficiency (%), flow properties and in-vitro dissolution study. The 
stevioside loaded pellets (STL 4) showed yields (92.36%), drug loading efficiency (86.60%), friability (0.74%), drug release 
(98.31%) within 60 min and good flow properties. The in vivo study indicates the significant reduction in blood glucose levels in 
alloxan induced diabetic rats after administration of stevioside loaded formulation (STL 4). The developed formulation of stevioside 
pellets can find its dual applications as a sugar substitute having the potential anti-hyperglycemic effect which can be given easily 
and safely to the diabetic patients.          
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1. INTRODUCTION 
Diabetes Mellitus is a chronic metabolic disorder which 
at present has affected more than 400 million people 
across the globe. It is the 7
th
 root cause of death 
universally and is progressing with a constant pace
1
.
 
Recent statistics and surveys have forecast to affect 592 
million people with diabetes by 2030 globally
2
. 
Likewise, in India, it is threatened seriously with the 
highest number (32 million in 2000) of the diabetic 
population followed by China and USA
3
. Moreover, it 
has been proposed that from 2006 to 2025 the diabetic 
population will grow rapidly from 40 million to 69.9 
million
4
. The hyperglycemic state of a diabetic patient 
is difficult to treat but the blood glucose level can be 
managed by administration of a daily dose of the 
antidiabetic drug
5
. Antidiabetic drug from natural 
sources is preferred because of their less toxicity and a 
negligible side effect on to the body
6
.     
Stevioside is a sweet tasting glycoside present in large 
quantity in the leaves of Stevia rebaudiana Bertoni 
(Asteraceae)
 7
. It is composed of stevia, a diterpenic 
carboxylic alcohol with three glucose molecules 
attached to an aglycone, the steviol moiety
8
. It is about 
200-300 times sweeter than sugar; its sweetness 
potency is alike to that of aspartame
9
. Stevia is finding 
its worldwide application as a non-caloric sweetener 
10
.
 
Apart from its sweetness properties, the stevioside has 
promising contraceptive 
11
,
 
antihypertensive 
12
 and anti-
diabetic potential
13-15
. Stevioside has been used for 
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many years in the treatment of diabetes in several 
countries
16, 17
. The antidiabetic potential of stevioside is 
due to the stimulation of insulin secretion from the beta 
cells of the pancreas 
18
.
 
 
The present investigation aimed to develop a multi-
particulate system consisting of stevioside loaded 
pellets. Multi-particulate system have many advantages 
over the single unit dosage form like, better distribution 
in gastrointestinal tract, less dependent on gastric 
emptying, avoidance of local irritation, less inter and 
intra-subject variability
19
 and therefore considered for 
present investigation. Stevioside being a non-calorie 
sweetener can be given as a substitute for sugar to the 
diabetic patient. Besides, a sweetener stevioside 
through its anti-hyperglycemic action helps to regulate 
the blood glucose level. Therefore, the loaded pellets 
were evaluated for its antidiabetic potential.              
2. MATERIAL AND METHODS 
Stevioside powder was procured from Yucca 
Enterprises, Mumbai, India. Glibenclamide was a kind 
gift sample received from Alkem Laboratories, 
Mumbai, India. The non-pareil pellets were obtained 
from Zim Laboratories, Nagpur. HPMC-K4M was 
provided by the Colorcon Asia Pvt. Ltd., Mumbai, 
India. Polyvinyl pyrrolidone (PVP) K30 was purchased 
from Himedia Ltd., India.  The alcohol and the other 
chemical used were purchased from Loba Chemie, 
Mumbai, India. 
2.1 Method of loading of stevioside pellets  
The loading on pellet was carried out by two methods 
i.e., 1) Solvent evaporation and 2) Suspension layering 
method. 
2.1.1 Solvent evaporation method  
In this method, the stevioside powder in different 
weight ratios (1 to 4 %w/v) (Table 1) was dissolved in 
ethanol (50mL). The mixture was sonicated for 15 min 
to ensure complete solubilization of the compound. The 
suitable quantity of pellets (100mg/10mL) was 
incorporated into the mixture. The mixture was then 
kept at 80
o
C in hot air oven for about 45 min. After a 
specific time interval, the loaded pellets were collected 
and stored properly at ambient temperature until further 
use.        
        
Table 1: Method of formulation stevioside loaded pellets 
 
2.1.2 Suspension layering method  
This method involves wetting of the core material with a 
coating solution containing the drug. The process was 
continued with intermittent drying till the drug was 
completely loaded onto the core. Stevioside powder in 
different weight ratios (1 to 4 %w/v) was 
homogeneously dispersed in coating solution (Table 1). 
The coating solution composed of carrier HPMC-K4M 
(2% w/w) and binder PVP-K30 (15% w/w) dissolved in 
ethanol. Basic core non-pareil pellets (18#20) were 
transferred into coating pan (R & D coater) and the 
prepared coating solution was sprayed on it. The spray 
rate and inlet air temperature were adjusted in such a 
way that the drug coated pellets reached a temperature of 
about 37
o
C-42
o
C. The process parameters of a coating 
are given in Table 2. The talc was frequently added to 
the coating pan in order to avoid over wetting of the 
drug coated pellets as it may cause agglomeration. The 
dried pellets were sized on a sifter to remove 
agglomerates, broken pellets, and fine powder. The 
weight of the pellets was checked and the yield was 
noted. 
2.2 Evaluation of drug loaded pellets 
2.2.1 Percentage yield 
The yield of the pellets was determined as a percentage 
of the ratio of the initial weight of the pellets before the 
loading process to the final weight gain after loading. 
The percentage yield was calculated according to the 
following formula.    
Percentage yield (% w/w)          =         
Weight of pellets before loading/Total weight after loading of the drug 
×100 
 
 
                                              
Bath code 
Solvent evaporation method Suspension layering method 
Stevioside (% w/v) in ethanol Stevioside (% w/v) in coating solution 
STE1 1% - 
STE2 2% - 
STE3 3% - 
STE4 4% - 
STL1 - 1% 
STL2 - 2% 
STL3 - 3% 
STL4 - 4% 
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Table 2: The process parameters for stevioside loaded pellets 
 
               
2.2.2 Drug loading efficiency (%)  
Accurately weighed quantities of 100 mg stevioside 
loaded pellets were crushed in a mortar using a pestle 
and dissolved in 100 ml of 0.1 M HCl (pH 1.2). The 
solution was sonicated for 15 min and undissolved 
particles were removed by filtration through membrane 
filter (0.45µm). The stevioside content in the filtrate was 
determined by measuring the absorbance at λmax 331nm 
using UV spectrophotometer (Shimadzu UV-1800, 
Japan). 
The drug loading efficiency (%) was calculated 
according to the following relationship; 
 
                                                             Actual amount of stevioside found in pellets     
 Drug loading efficiency (% w/w) =     
     Theoretical amount stevioside in pellets 
 
2.2.3 Flow properties of pellets 
Stevioside loaded pellets were evaluated for flow 
properties such as angle of repose, Hausner’s ratio, bulk 
density, tapped density and Carr’s index. The angle of 
repose was determined by funnel method
 20
. The 
accurately weighed amount of pellets was taken in a 
funnel. The height of the funnel (h) was adjusted in such 
a way that the tip of the funnel just touches the apex of 
the heap of the pellets. The pellet was allowed to flow 
through the funnel on to the surface. The diameter of the 
formed cone of the pellets was measured and angle of 
repose was calculated using the fallowing formula; 
Tan ɵ= h/r or ɵ= tan h/r 
Where, ɵ= angle of repose, 
h= height of pile, 
r= radius of pile base 
Bulk density and tapped density was determined by 
cylinder method
21
. The pellet free of any agglomerates 
was introduced into a 10 mL measuring cylinder. After 
the initial volume was noted, the cylinder was allowed to 
fall under its own weight onto a hard surface from the 
height of 2.5 cm at 2 sec intervals the tapping was 
continued until no further change in the volume was 
noted. The bulk volume and tapped volume was noted 
and density was calculated.   
2.2.3 Friability of pellets 
Friability of pellets was determined using Roche 
friabilator testing apparatus. Previously weighed pellets 
were put into the friabilator. The friabilator was revolved 
at a speed of 25 rpm for 4min. After the revolution the 
fines and broken pellets were separated and intact pellets 
were weighed. The percentage friability was calculated 
as total weight loss of pellets during the revolution.     
2.2.4 In vitro dissolution studies 
The In vitro drug dissolution study was performed on 
stevioside loaded pellets filled in capsule using USP 
dissolution test apparatus II (Electrolab TD7-08L, 
Mumbai, India). The capsule containing loaded pellets 
equivalents to 15 mg of stevioside was placed in 900 mL 
of 0.1M HCl (pH 1.2) dissolution medium maintained at 
37±0.5
o
C and 50 rpm of paddle speed. At definite time 
intervals, 5 mL aliquots were withdrawn, filtered, 
suitably diluted and analyzed for drug release for 60 min 
at 331 nm using UV-spectrophotometer (Shimadzu UV-
1800, Japan).  
2.2.5 Fourier transmission infrared (FTIR) 
spectroscopy 
FTIR spectrum of pure stevioside powder, nonperial 
pellets and stevioside loaded pellets were recorded by 
potassium bromide dispersion techniques. About 2-3 mg 
of each sample were mixed well to form a fine powder 
with KBr and analyzed using FTIR spectrophotometer 
(IRAffinity-1, Kyoto, Japan) in the scanning wavelength 
region between 4000 and 600 cm
-1. 
The spectrums 
recorded were carefully examined for any interaction 
between drug and excipients.     
 
Sr. No. Process Parameter       Specification 
1. Pan size 4 inch 
2. Batch size  10 g 
3. Spray rate   0.5-2 g/min 
4. Air flow  0.3-1.5 bar 
5. Atomizing  air pressure  2lb/in
2
 
6. Nozzle diameter  0.8 mm 
7. Inlet air temperature   60-70
o
C 
8. 
9. 
10. 
Product temperature  
Pan speed 
Spray gun type 
40-50
o
C 
26 rpm 
Cone type 
X 100 
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2.2.6 Stability studies 
The optimum formulation was subjected stability testing 
as per the International Conference on Harmonization 
(ICH) guidelines
22
. The stevioside loaded pellets were 
filled manually in hard gelatin capsule. The capsules 
were sealed in aluminum packaging and kept in a 
polyethylene bottle. The packed container was subjected 
to accelerated stability testing at 40±2
o
C and 75± 5% 
RH in the humidity chamber (Bio-Technics, India, Ltd.). 
After the specific time intervals (0, 45 and 90 days) the 
capsules were withdrawn and observed visually for 
change in appearance, and drug release (%).            
2.3 In vivo anti-diabetic study 
2.3.1 Experimental subjects 
All experiments and protocols performed in the study 
were approved by the Institutional Animal Ethical 
committee (Reg. No. KNCOP/ R&D/ AN-PROT/2012-
13/02), Kamla Nehru College of Pharmacy, Butibori, 
Nagpur, India. The healthy Swiss albino rats of either 
sex weighing 150-200 g were employed for the study 
and were procured form Shree Farm House, Bhandara, 
India. The animals were housed under standard 
conditions of temperature (25±2
o
C) and (12:12 hr 
light/dark cycle) with free access to water. 
2.3.2 Study protocol 
The Swiss albino rats were divided into five groups each 
containing six rats (n=6) and were placed in separate 
metabolic cages. The blood glucose levels of each 
animal were determined in fasting state with free access 
to water. Group I (control group), the animals received 
normal saline solution through the oral route. Group II 
(diabetic untreated control), diabetes was induced in 
animals by giving alloxan monohydrate intra-
peritonially. Group III (standard control), the animals 
received the standard drug. Group IV and Group V were 
treated with the optimized formulation of stevioside 
pellets containing 15 mg and 30 mg of stevioside 
respectively and given orally in the form of suspension 
(prepared with 0.5% CMC) by gastric gavage. Diabetes 
was induced in animals by the intraperitoneal injection 
of alloxan monohydrate at a dose 150mg/kg body 
weight. After 48 hr of injection, blood glucose level was 
measured every day up to seven days. On the seventh 
day, the animals with blood glucose levels above 250 
mg/dL were considered as diabetic and used for the 
study. Group III animals were treated with standard 
glibenclamide at a dose of 10 mg/kg body weight and 
served as reference. The standard drug and test 
formulation were given daily for a period of 21 days. 
The blood samples were withdrawn at 0hr, 1hr, 2hr, 3hr, 
4hr and 24hr, after treatment by tail tipping method. 
Blood samples were analyzed for the blood glucose 
levels, using glucometer (Glucometer One Touch, 
Horizon, Life Scan, Johnson and Johnson Ltd.). A drop 
of blood obtained by tipping tail was placed on 
customized test strips inserted on glucometer and blood 
glucose level was read from the digital display
23
.
 
 
2.3.3 Statistical analysis 
Data represented with mean and standard deviation 
subjected to statistical analysis using one- way analysis 
of variance. The statistical probability (p) value less than 
0.05 was considered to be significant. 
3. RESULTS AND DISCUSSION 
The stevioside loaded pellets were found to be whitish 
spherical shape, uniform in size and had the smooth 
appearance. The process parameters for coating were 
critically monitored and adjusted for optimum 
performance. 
3.1 Percentage yield and Drug loading efficiency (%)   
The physical evaluation of stevioside loaded pellets 
showed good practical yield (75-92%), excellent drug 
loading efficiency (69-86%) (Table 3). The yield of 
loaded pellets prepared with solvent evaporation method 
was found to be low as compared to suspension layering 
method. The low yield of pellets with solvent 
evaporation method might be due to the dissolution or 
leaching of the drug in a solvent that remains stick to the 
wall of the container after evaporation of the solvent. 
The good loading efficiency was noted in loaded pellets 
prepared with suspension layering method. Therefore, 
suspension layering method can be exploited as the 
better method for loading of stevioside on pellets. The 
results indicated that with the increase in drug 
concentration in the appropriate solvent the loading 
efficiency also increases.  
 
Table 3: The evaluation parameters of stevioside loaded pellets 
Batch code Yields of Pellets (%) Drug loading efficiency 
(%) 
Friability (%) 
STE1 75.24±2.34 69.92±3.49 0.76±0.12 
STE2 76.36±1.87 77.33±1.15 0.66±0.13 
STE3 78.32±2.36 78.47±0.78 0.57±0.08 
STE4 79.23±1.98 79.61±1.26 0.76±0.16 
STL1 84.65±1.54 80.35± 1.18 0.84±0.11 
STL2 86.32±0.97 81.68±1.42 0.79±0.09 
STL3 89.56±1.38 83.61±1.25 0.62±0.16 
STL4 92.36±1.47 86.60±1.34 0.74±0.07 
The values are expressed as a mean ± standard deviation, n=3. 
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Table 4: Flow properties of stevioside loaded pellets 
Batch code Bulk density (g/cm
3
) Tapped density (g/cm
3
) Angle of repose (θ) 
STE1 0.516 0.598 26.5 
STE2 0.513 0.587 26.9 
STE3 0.518 0.585 26.2 
STE4 0.522 0.591 26.3 
STL1 0.519 0.611 25.6 
STL2 0.526 0.604 25.9 
STL3 0.541 0.608 25.8 
STL4 0.532 0.602 24.5 
 
3.2 Flow Properties 
All the batches showed good flow properties (Table 4) 
which are desired for proper filling of pellets into a 
capsule.     
 
3.3 Friability of pellets 
The friability was found to be less than 1% for all the 
batches of stevioside loaded pellets (Table 3) suggesting 
the formulation having required strength and 
resistibility.  
3.4 In vitro dissolution studies 
The in-vitro drug release studies were performed for all 
the batches of stevioside loaded pellets in 0.1M HCl (pH 
1.2). The dissolution profile of all the formulation 
batches is presented in Fig 1. The formulations STE1-
STE4 shows drug release 82.18-88.12%, whereas the 
formulation STL1-STL4 indicate the drug release 92.81-
98.31% at the end of 60 min. The higher percentages of 
drug release were obtained with the pellets loaded with 
drug by suspension layering method. Among all the 
formulations, batch STL4 shows higher drug release 
(98.31%). The in-vitro dissolution data were dealt 
statistically with one-way ANOVA and the results show 
the difference in drug release rate are statistically 
significant. 
 
 
Figure 1: Cumulative drug release (%) from stevioside loaded pellets. (SD ± Mean, n=3) 
 
3.4 Fourier transmission infrared (FTIR) 
spectroscopy 
FTIR spectrum of pure stevioside and stevioside loaded 
pellets were presented in Figures 2 and 3. FTIR 
spectrums of stevioside indicate the presence of major 
functional groups in the structure which supports its 
identity. The principle peaks of stevioside observed 
were 2751 (C-H), 2812 (C=C-H), 1384 (O-H), 1655.48 
(>C=O) and 1957 (lactone ring). All the functional 
peaks were found to be retained in stevioside loaded 
pellets suggesting no any interaction of drug-excipients. 
 
Figure 2: Fourier transform-Infrared spectrum of stevioside powder 
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Figure 3: Fourier transform- Infrared spectrum of stevioside loaded pellets 
 
3.6 Stability studies 
The stability testing was performed on selected 
formulation SLT 4. The results indicate that there were 
no notable changes in physical appearance and drug 
release after subjecting the formulation at 40°C ± 2°C & 
75% ±5% RH for 90 days (Table 4). Therefore, the 
formulation was found to be stable and retain its stability 
for 90 days. 
Form the observations, the batch STL 4 showed yields 
(92.36%), drug loading efficiency (86.60%), friability 
(0.74%), drug release (98.31%) within 60 min and good 
flow properties and therefore selected as the optimum 
formulation for carrying in-vivo antidiabetic study.    
 
Table 5: Stability testing data of optimized formulation STL 4 
Days Physical appearance Cumulative drug release (%) 
 Before storage  
0 White texture, smooth appearance 98.31±0.43 
After storage 
45 No changes observed 97.43±0.64 
90 No changes observed 97.03±0.98 
*All values are expressed as mean ± SD, n=3.  
          
3.7 In vivo anti-diabetic study 
The results of the  in-vivo antidiabetic study in diabetes-
induced rats showed a significant decrease in blood 
glucose levels after oral administration of optimized 
formulations of stevioside. In order to determine the 
acute effects on blood glucose levels, the stevioside 
loaded pellets in two dose levels were administered 
orally. The variation in the blood glucose levels of 
individual rats was determined at 0h, 1h, 2h, 3h, 4h and 
after 24h. Consequently, the significant reduction in 
blood glucose level was noted in diabetic rats treated 
with the SLT4 (15mg) and SLT4 (30mg) formulations 
(Table 6).   
 
Table 6: Acute hypoglycemic effect of stevioside loaded pellets on alloxan induced diabetic rats   
Groups  Time (h)    
0h 1h 2h 3h 4h 24h 
Control 84.21±1.53 91.45±2.34 95.84±1.95 88.23±1.17 86.41±1.05 80.26±2.31 
Standard 340.23±2.97* 272.42±3.59** 205.64±4.12*** 154.29±2.14* 121.33±3.47* 119.25±1.82** 
SLT 4 
15mg 
338.24±4.52* 335.46±4.28** 329.87±3.54* 342.54±5.24* 337.45±4.21** 310.25±5.46* 
SLT 4 
30mg 
341.28±3.87* 333.78±3.44** 327.46±4.68*** 349.65±3.20*** 330.25±2.98** 287.24±5.18** 
Each value represents mean ± SEM, n=6, *p<0.05 denote value significantly different from control, **p<0.01, ***p<0.001 denote 
value significantly different from diabetic control. SEM: Standard error of the mean, p: Probability value. 
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Table 7: Sub-acute hypoglycemic effect of stevioside loaded pellets on alloxan induced diabetic rats 
Groups  Days   
1-day 7day 14day 21day 
Control 91.23±4.71 87.66±5.12 84.34±3.28 89.48±2.8 
Diabetic control 341.74±4.42* 355.64±6.47* 369.15±8.67* 388.57±9.71* 
Standard 340.27±8.28* 244.25±7.34*** 194.56±7.26*** 127.71±8.64*** 
SLT 4 15mg 335.52±6.74* 287.29±5.21** 217.36±4.63** 176.34±5.57** 
SLT 4 30mg 333.38±5.84* 268.47±4.87*** 204.59±6.14*** 158.73±4.45*** 
Each value represents mean ± SEM, n=6, *p<0.05 denote value significantly different from control, **p<0.01, ***p<0.001 denote 
value significantly different from diabetic control. SEM: Standard error of the mean, p: Probability value. 
 
CONCLUSION  
The pellets were loaded successfully with stevioside 
using solvent evaporation and suspension layering 
methods. The loaded pellets were evaluated critically for 
various parameters. The in-vivo antidiabetic study in 
alloxan induced rats shows the significant reduction in 
blood glucose level after administration of selected 
formulation. Therefore, the developed pellets can be 
exploited as a potential antidiabetic formulation to the 
diabetic patient. The stevioside being sweet in nature 
could satisfy the desire of sweet in diabetic patients 
along with its promising anti-hyperglycemic effect. 
ACKNOWLEDGEMENT 
We sincerely thanks to the secretary of the Kamla Nehru 
College of Pharmacy, Butibori, Nagpur, India, for 
providing the infrastructural facility for carrying out the 
research work.  
DECLARATION OF INTEREST  
We declare that there is no conflict of interest with the 
content of this article. 
                             
REFERENCES 
1. Horenstein RB, Shuldiner AR. Genetics of diabetes. Rev 
Endocr Metab Disord 2004; 5: 25-36. 
2. Wild S, Roglic A, Green R, King H. Global prevalence of 
diabetes estimates for the year 2000 and projections for 2030. 
Diabetes Care 2004; 27: 1047-1053. 
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 
1995-2025: prevalence, numerical estimates, and projections. 
Diabetes Care 1998; 21: 1414-1431.   
4. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. 
Epidemiology of type 2 diabetes: Indian scenario. Indian J 
Med Res 2007; 125: 217-230.  
5. Barwal I, Sood A, Sharma M, Singh B, Yadav S C. 
Development of stevioside Pluronic-F-68 copolymer based 
PLA- nanoparticles as an antidiabetic nanomedicine. Colloids 
and surface B: Biointerface 2013; 101:510-516. 
6. Bailey CJ, Day C. Traditional plant medicines as treatments 
for diabetes. Diabetes Care 1989; 12:553-564. 
7. Madan S, Ahmad S, Singh G N, Kohli K, Kumar Y, Singh R, 
Garg M. Stevia rebaudiana (Bert.) Bertoni- A review. Indian 
J Nat Prod Resou 2010; 1(3): 267-286.   
8. Mondaca RL, Galvez AV, Bravo LZ, Hen KA. Stevia 
rebaudiana Bertoni, source of a high-potency natural 
sweetener: A comprehensive review on the biochemical, 
nutritional and functional aspects. Food Chemistry 2012; 
132:1121-1132. 
9. Prakash I, DuBois GE, Cols JF, Wilkens KL, Fosdick LE. 
Development of rebiana, a natural, non-caloric sweetener. 
Food Chem Toxicol 2008; 46(7):S75-82.  
10. Goyal SK, Samsher, Goyal RK. Stevia (stevia rebaudiana) a 
bio-sweetener: a review. Int J Food Sci Nutr. 2010; 61(1): 1-
10.  
11. Melis MS. Effects of chronic administration of Stevia 
rebaudiana on fertility in rats. J Ethanopharmacol 1999; 
67:157-161.  
12. Jeppesen PB, Gregersen S, Rolfsen SE, Jepsen M, Colombo 
M, Agger A, Xiao J et al. Anti-hyperglycemic and blood 
pressure- reducing effects of stevioside in the diabetic Goto-
Kakizaki rat. Metabolism 2003; 52:372-378.   
13. Jeppesen PB, Gregersen S, Alstrup KK, Hermansen K. 
Stevioside induces anti-hyperglycemic, insulinotropic and 
glucagonostatic effects in vivo: studies in the diabetic Goto-
Kakizaki (GK) rats. Phytomedicine 2002; 9:9-14. 
14. Kujur RS, Singh V, Ram M, Yadava HN, Singh KK, Kumari 
S, Roy BK. Anti-diabetic activity and phytochemical 
screening of crude extract of Stevia rebaudiana in alloxan 
induced diabetic rats. Pharmacog Res 2010; 2:258-263. 
15. Geuns JM. Stevioside. Phytochemistry 2013; 64:913-921.  
16. Chatsudthipong V, Muanprasat C. Stevioside and related 
compounds: Therapeutic benefits beyond sweetness. 
Pharmcol Ther 2009; 121(1):41-54.    
17. Roberts A, Munro I. Stevioside and related compounds: 
Therapeutic benefits beyond sweetness. Pharmcol Ther 2009; 
122(3):e1-e2. 
18. Jeppesen PB, Gregersen S, Poulsen CR, Hermansen K. 
Stevioside acts directly on pancreatic beta cells to secrete 
insulin: action independent of cyclic adenosine 
monophophate and adenosine triphosphate- sensitive K
+ 
channel activity. Metabolism 2000; 49:208-214.  
19. Laila F, Chandran SS. Multiparticulate formulation approach 
to colon specific drug delivery: current perspectives. J Pharm 
Sci 2006; 9(3): 327-338. 
20. Aulton ME. Pharmaceutics: The Science of Dosage Form 
Design. 2
nd
 ed. Churchill-Livingstone, London. 2002. p.205-
206.  
21. Sinko P J. Martin’s. Physical Pharmacy and Pharmaceutical 
Sciences. 5
th
 ed. Lippincott Williams & Wilkins; 
Philadelphia. 2007. p. 553-556. 
22. Orhan N, Aslan M, Orhan DD, Ergun F, Yesilada E. In-vivo 
assessment antidiabetic and antioxidant activities of 
grapevine leaves (vitis vinifera) in diabetic rats. J 
Ethanopharmacol. 2006; 108; 280-286. 
23. Note for guidance on stability testing. Stability testing of new 
drug substances and products; available from: URL: 
http://www.tga.gov. access on  12/12/2016. 
 
